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Sllmmsl'y 
Males from the BXSB murine strain (H-2  b) spontaneously develop an autoimmune syndrome 
with features of systemic lupus erythematosus (SLE), which results in part from the action of 
a mutant gene (Yaa) located on the Y chromosome. Like other H-2  b mice, the BXSB strain 
does not express the class II major histocompatibility  complex antigen, I-E.  Here we report 
that the expression of I-E (Ec~EB  b) in BXSB males bearing an E& transgene prevents hyper- 
gammaglobulinemia, autoantibody production,  and subsequent autoimmune glomerulonephritis. 
These transgenic  mice bear on the majority of their B cells not only I-E molecules, but also 
an I-E ol chain-derived peptide presented by a higher number of I-A  b molecules, as recognized 
by the Y-Ae monoclonal antibody. The I-E + B cells appear less activated in vivo than the I-E- 
B cells, a minor population.  This limited activation of the I-E + B cells does not reflect a func- 
tional deficiency of this cell population, since it can be stimulated to IgM production in vitro 
by lipopolysaccharides at an even higher level than the I-E- B cell population.  The development 
of the autoimmune syndrome in the transgenic and nontransgenic bone marrow chimeric mice 
argues against the possibility that the induction of regulatory T cells or clonal deletion of potential 
autoreactive T cells as a result of I-E expression is a mechanism of the protection conferred by 
the E& transgene. We propose a novel mechanism by which the Ecff transgene protects BXSB 
mice against SLE: overexpression of I-E c~ chains results in the generation of excessive  amounts 
of a peptide displaying a high affinity to the I-A  b molecule, thereby competing with pathogenic 
autoantigen-derived peptides for presentation by B lymphocytes and preventing their excessive 
stimulation. 
T 
he BXSB mouse strain spontaneously develops a progres- 
sive and lethal autoimmune disease, similar to human 
SLE, which affects male animals much earlier than females 
(1, 2). Cell transfer and Y chromosome transfer studies have 
dearly demonstrated that the Y chromosome-linked  autoim- 
mune acceleration (Yaa) gene present in the Y chromosome 
of the BXSB strain is responsible, in mice predisposed to au- 
toimmune diseases, for the accelerated autoimmune abnor- 
malities and immunopathological lesions (3-6). In addition, 
it has been demonstrated that the MHC genes play a critical 
role in the development of SLE-like autoimmune syndrome 
in BXSB mice (7) and in their F1 hybrids with NZB mice 
(Merino, R., M. Iwamoto, and S. Izui, manuscript in prepa- 
ration): the H-2  b haplotype appears to be associated with the 
development of the autoimmune disease, whereas the H-2  d 
haplotype protects  against  this  disease. Since BXSB and 
(NZB x  BXSB)F1 mice bearing the H-2  b haplotype do not 
express one of the class II MHC antigens,  I-E (because of 
the deletion of the promoter region of the Eol gene [8]), the 
inhibitory effect of the H-2  d haplotype may in part be re- 
lated to the expression of the I-E molecule.  In fact, it has 
been shown that I-E molecules could exhibit  a suppressive 
activity on immune responses (9), and more recently the ex- 
pression of I-E molecules through an I-E o~ chain transgene 
was found to result in the prevention  of autoimmune dia- 
betes in NOD (I-E-) mice (10-13). In the present study, we 
found that the expression of a transgene encoding the I-E 
c~ chain, E&, is highly protective against the development 
of  the lupuslike autoimmune disease  in BXSB mice, and defined 
the possible protective mechanism(s) conferred by the expres- 
sion of this transgene. 
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Generation of BXSB  Eot  a Transgenic and BXSRIgh ~ Congenic 
Mice.  BXSB mice were purchased from The Jackson Laboratories 
(Bar Harbor, ME). A 14-kb SaclI/XhoI fragment containing  the 
entire  E& gene sequence (14) was microinjected  into fertilized 
eggs of BXSB mice, as described (15). Mice were screened for the 
transgene by the surface staining of PBMC using an anti-I-E mAb, 
Y-17 (16), as described below. 
BXSB.Igh  a congenic mice were established by transfer of the 
Igh' gene complex of the B.C20/Icr  strain as follows: BXSB fe- 
males were mated with B.C20/Icr  males, male offsprings which 
carry the Igh ' allotype, as determined by ELISA (described below), 
were then backcrossed  with BXSB females for 11 generations. Then, 
females carrying the Igh" allotype were mated with BXSB males 
to introduce  the Yaa gene. The BXSB.Igh' novel strain was ob- 
tained by mating  female and male BXSB Igh  vb heterozygotes at 
the 12th backcross generation. 
Southern Blot Analysis.  5/~g of high molecular weight genomic 
DNA prepared from tails of BXSB mice were digested with SacI, 
electrophoresed on a 1.0% agarose gel, and transferred to a nylon 
membrane (GeneScreen Plus; Du Pont Co., Boston,  MA) as de- 
scribed (17). Hybridization  was carried out under high stringency 
with a 32P-labeled 2.6-kb SalI fragment containing  the first exon 
of the Ec~  d gene (18), which recognizes two 1.9 and 2.9-kb frag- 
ments of the injected E& gene and a 4.2-kb fragment of the endo- 
genous defective Ecr ~ gene in Sad-digested  DNA (see Fig. 1 A). 
Northern Blot Analysis.  Total RNA was extracted,  using the 
guanidine isothiocyanate/CsCl method (19), from spleen, thymus, 
lymph nodes, liver, kidneys, lungs, and brain of BXSB mice. RNA 
(30/zg) were electrophoresed on a 1% formaldehyde-containing 
agarose gel, transferred to nylon membrane, and hybridized with 
a 32P-labeled 3.5-kb SalI fragment containing exons 2, 3, and 4 of 
the E~ gene (18) or 32P-labeled cDNA corresponding to 3-actin. 
Cytofluorometric  Analysis.  The expression of I-E and/or I-A mol- 
ecules in peripheral blood and spleen cells was analyzed by staining 
first with FITC-conjugated anti-mouse/z chain mAb (LO-MM-9) 
(20), and then incubating with biotinylated anti-I-E (Y-17) and/or 
anti-I-A b (Y-3P) mAb  (21), followed by PE-conjugated  avidin 
(Caltag  Laboratories, San  Francisco, CA)  and  analyzed with  a 
FACScan  |  (Becton Dickinson & Co., Mountain  View, CA). The 
expression of the I-Ab-E~ peptide complexes, recognized by the 
Y-fie mAb (22, 23), was determined by two different staining proce- 
dures. First, spleen cells were first stained with FITC-conjugated 
anti-mouse # chain mAb (LO-MM-9),  and then incubated with 
biotinylated Y-fie mAb, followed by PE-conjugated avidin. Second, 
spleen cells were first stained with FITC-hbeled anti-I-E (Y-17) mAb, 
then with PE-conjugated goat anti-mouse/z chain Abs (Caltag 
Laboratories), and incubated with biotinylated Y-fie  mAb, followed 
by Streptavidin-RED670  TM (Gibco BILL, Gaithersburg, MD). The 
expression of V/3 segments of TCR in Thy-1 + lymph node cells 
was analyzed as described previously (7). Monocytes in peripheral 
blood were enumerated using anti-Mac-1 mAb (M1/70) (24) fol- 
lowed by FITC-conjugated  goat anti-rat  IgG Abs. Surface IgM  ' 
and IgM  b positive cells in peripheral blood from bone marrow chi- 
meric  mice were stained with biotinylated  mAb,  RS-3.1  (anti- 
IgM  ')  (25), and  MB86  (anti-IgM b) (26), followed by PE-con- 
jugated avidin. 
Histopathology.  Samples  of all major organs were obtained at 
autopsy, and histological sections were stained with either the peri- 
odic acid-Schiff reagent or with hematoxylin eosin. Glomerulone- 
phritis was scored on a 0-4 scale based on the intensity and extent 
of histopathological  changes, as described previously (5). 
Serological Assays.  Serum  levels  of total  IgG,  IgG Abs 
against  single-stranded  DNA or human  IgG (HGG)  1 and 
the allotype of anti-DNA Abs were determined by ELISA 
as described (6, 27, 28). Anti-DNA or anti-HGG activities 
in sera are expressed in titration units as described previously 
(6, 27). Serum levels of gp70-anti-gp70 immune complexes 
(gp70 IC) were quantified by an ELISA combined with the 
precipitation of the serum with polyethylene glycol (average 
molecular weight 6,000), as described (6, 7). Results are ex- 
pressed as/~g/ml of gp70 complexed with anti-gp70 Abs by 
referring to a standard curve obtained from NZB sera with 
known amounts of gp70. Serum levels of Igh ' and Igh  b al- 
lotypes were determined by a previously described ELISA (28). 
Isolation of I-E+ IgM + and I-E-IgM + B Cells, and Cell Cul- 
ture.  Spleen cells,  depleted  of Thy-1 + cells  by treatment 
with anti-Thy-l.2 (AT83) mAb (29) and rabbit complement 
from transgenic  BXSB mice were stained for surface IgM 
and I-E molecules as described above. Then,  I-E +  IgM + or 
I-E-IgM +  B  cells  were  purified  by  a  FACStar  |  (Becton 
Dickinson & Co.) For the spontaneous IgM and IgG secre- 
tion, 10  s I-E +  IgM + or I-E-IgM + B cells were incubated in 
200/~1 DME supplemented with additional amino acids,  10 
mM Hepes, 5  x  10 -s M  2-ME, and 10% FCS for 24 h at 
37~  in a humidified incubator containing 5% CO2 in air. 
For the LPS-induced IgM production,  3  x  104 I-E+IgM + 
or I-E-IgM + B cells in 200/zl culture were stimulated with 
50/~g/ml  of Escherichia coli LPS (Difco Laboratories,  Inc., 
Detroit, Michigan) for 5 d. IgM and IgG concentrations in 
supernatants  were determined by ELISA (6,  7). 
Preparation of  Bone Marrow Chimeras.  2-mo-old BXSB fe- 
male recipients were irradiated at 850 rad and reconstituted 
with bone marrow cells (BMC) from 3-4-too-old BXSB mice. 
A  mixture  of 107 viable BMC were intravenously injected 
into irradiated  recipients  as detailed in Table  1. 
Statistical Analysis.  Statistical  analysis was performed with 
the Wilcoxon two-samples test. Probability values >5% were 
considered insignificant. 
Results and Discussion 
To explore a possible protective effect of the I-E molecule 
on the development of SLE in autoimmune BXSB male mice, 
we  introduced  the  Eod  gene  into  this  strain,  and  nine 
founder transgenic BXSB mice were generated. A line from 
one of these founder mice, BXSB-E-1, which contains ap- 
proximately 50 copies of the Ec~  a transgene (Fig.  1 A), was 
established and analyzed in more detail.  The Eot transcript 
was strongly expressed in thymus, spleen, and lymph nodes, 
and at  a low level  in lungs,  liver,  and kidneys (Fig.  1 B), 
in  agreement  with  previous  results  in  I-Eo~  transgenic 
C57BL/6 (B6.Ec~) mice (14).  Comparative measurements 
1  Abbreviations  used in this!~fer: BMC, bone marrow cells; B6.Etxd, I-Eo~ 
transgenic C57BL/6; gpT0 IC, gp70-anti-gpT0 immune complexes;  HGG, 
human IgG. 
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Group  BMC donor  Recipient 
I*  BXSB.Igh" male (Igh  ")  BXSB female 
+ 
BXSB-E-1 male (Igh  b) 
II  BXSB.Igh' male (Igh  ")  BXSB-E-1  female 
+ 
BXSB male (Igh  b) 
III  BXSB.Igh' male (Igh  ')  BXSB female 
+ 
BXSB male (Igh  b) 
IV  BXSB.Igh" female (Igh  ')  BXSB female 
+ 
BXSB-E-1 female (Igh  b) 
" 2 mo after the reconstitution, the chimerism was checked by measur- 
ing serum levels of Ig allotype and by enumeration of IgM~ and IgM  b 
allotype-positive  circuhting B cells. These analyses  showed that both popu- 
lations of donor B cells were equally repopulated in recipient mice (data 
not shown). 
of Ecx mRNA and fl-actin mRNA levels, as determined by 
densitometric analysis on Northern blots,  showed an '~20- 
fold-greater expression ofEot mRNA in the spleen from the 
BXSB-E-1 mice than in BXSB.H-2  b/a heterozygous mice. 
Expression of the Ecx gene product was examined by the 
surface staining of spleen cells using an anti-IE mAb, Y-17, 
which recognizes combinations of Ecx and E3 molecules of 
various haplotypes, including Eo~Efl  b (16). Spleen cells from 
the BXSB-E-1 mice expressed the I-E molecule exclusively 
on surface IgM + B cells at levels similar to those found on 
the spleen B cells of CBA/J (H-2  k, I-E +) mice (Fig. 1 C). 
The transgenic  mice contained, however, a significant per- 
centage of I-E-IgM + B cells (about 15-20%  of splenic B 
cells), which expressed the I-A  b molecule at  a density as 
high as that found on I-E +  IgM + B cells (data not shown). 
Such a disparate expression of I-E antigens  among B cells 
has been previously  noted in  other Eot  a transgenic  mice 
generated using transgenes containing only a short 5' flanking 
sequence of the E~ gene (30). However, our E& transgene 
construct contains about 4 kb of 5' flanking sequence, which 
is enough to allow an appropriate expression of E& mRNA 
and I-E c~ chain. In the spleens of B6.Eot  a transgenic mice 
generated using  the  same  construct  (14), no  significant 
numbers of I-E-IgM + B cells were found (Fig. 1 C). The 
presence of I-E-IgM + B cells may thus be a peculiarity of 
the BXSB-E-1 mice or of mice with a lupus background. 
It is also possible that the I-E- and I-E + populations  may 
represent two different subsets of B cells at different stages 
of activation or differentiation.  In the transgenic mice, the 
I-E molecule was also present on a very small fraction of un- 
stimulated monocytes, but on most IFN-3~-stimulated  mono- 
cytes, as is also the case for normal I-E + mice (data not 
shown). Immunofluorescence staining with the Y-17 antiq-E 
mAb of thymus cryosections of these transgenic mice showed 
typical confluent staining of the medulla and reticular staining 
of the cortex (data not shown). 
Expression of the I-E antigen in these transgenic mice was 
accompanied by a decrease in the V35 + and V311 + T cells, 
which potentially contain anti-I-E autoreactive T cells. Vfl5 + 
and V311  + represented  1.48 and 2.91%  of Thy-1 + cells 
from the BXSB-E-1 lymph nodes, as compared with 7.48 
and 5.14%,  respectively, in the BXSB nontransgenic I-E- 
littermates. In contrast, no differences were found in the per- 
centages of Vfl6 + and VflS.2 + cells between the transgenic 
mice (10.55 and 12.45%,  respectively) and their nontrans- 
genic littermates (8.04 and 12.12%). The extent of this deple- 
tion of Vfl5 + and V311 + T cells, presumably due to I-E ex- 
pression in the transgenic mice, was comparable with that 
observed in I-E + BXSB H-28/a heterozygous mice (7). The 
spleen cells  of  the BXSB-E-1 mice induced a significant  prolifer- 
ation of I-E- BXSB lymphocytes in MLC (data not shown). 
The lupuslike autoimmune syndrome developing in the 
male  nontransgenic  I-E-  littermates  was  dramatically 
prevented in the male BXSB-E-1 transgenic mice. Whereas 
50%  of the nontransgenic I-E male littermates  had died of 
glomerulonephritis within the first 8 mo, with no survivors 
after 1 yr, none of the transgenic mice died within the first 
year (Fig. 2 A). Kidney histology at 8 mo showed in I-E- 
male mice a severe  glomerulonephritis with increased mesan- 
gial and glomerular cellularity, obliteration of glomerular ar- 
chitecture, and tubular cast formation. In contrast, transgenic 
males exhibited minimal glomerular changes (Fig. 3). In corre- 
lation  with  the renal  lesions, serum levels of total  IgG, 
nephritogenic gp70 IC (6, 7, 31, 32) and IgG anti-DNA au- 
toantibodies  in  the male transgenic  mice  at  6  mo were 
markedly lower than those of their male nontransgenic lit- 
termates  ~  <0.001),  and almost comparable with those of 
female  BXSB mice (Fig. 2, B-D). Blood monocytosis, a unique 
abnormality characteristic of conventional BXSB male mice 
(33) was,  however, unaltered in transgenic  mice (percent 
Mac-1 + PBMC at 8 mo of age [mean of 5 mice _.  1 SD]: 
transgenic males, 20.6  _+  2.6%; transgenic females, 6.6  _+ 
0.9%; nontransgenic males, 19.5 _+ 5.8%; nontransgenic fe- 
males, 6.2 _+  1.2%). This indicates that monocytosis in BXSB 
males is neither a cause nor a consequence of the autoim- 
mune syndrome, but rather is somehow related to the nature 
of the Yaa mutation. This also suggests that the expression 
of the I-E c~ chain transgene prevents the development  of 
autoimmune responses, rather than the acceleration  effect  medi- 
ated by the Yaa gene in BXSB mice. This is further supported 
by our recent observation that the lupuslike autoimmune syn- 
drome developing in (NZB  x  BXSB-E-1)F~ female mice in 
the absence of the Yaa gene is similarly inhibited by the pres- 
ence of the E& transgene  (Iwamoto, M., R. Merino,  and 
S.  Izui,  unpublished  observation). 
The present results demonstrate that the expression of the 
I-E ot chain transgene prevents the autoimmune syndrome 
1191  Merino et al. Figure  1.  (A)  Southern  blot 
anal~ of  the Eot 8erie  in mmscac 
(BXSB-E-I,  BX.SB-E-7,  BX.SB- 
E-8)  or  nontransgenic  BXSB, 
C57BL/6  (B6) (H-2b), BALB/c 
(/-/-2  d) and their F1 hybrids (B6 
x  RALB) mice. The host BXSB 
mice carry a deletion in this re- 
gion, as other H-2  b mice (8), and 
their SacI-digested DNA yielded 
a 4.2-kb band, larger than those 
(1.9 and 2.9 kb) obtained from 
BALB/c DNA. DNA from trans- 
genie  mice  (BXSB-E-I, BXSB- 
E-7, BXSB-E-8) gave, in addition, 
the  two  1.9-  and  2.9-kb bands 
characteristic of the E& gene, in- 
dicating that these  mice contain 
the injected BALB/c E& gene. 
(B) Northern blot analysis of Ec~ 
mRNA from various tissues of the 
BXSB-E-1  mice.  As  controls, 
RNA  from  I-E +  BXSB.H-2 b/a 
(7) and I-E- BXSB (H-2  ~') spleens 
were also analyzed.  Positions  of 
18S and 28S ribosomal RNA are 
indicated. (C) Expression  of the 
I-E (EotaEfl  b) antigen on  spleen 
cells of the BXSB-E-1 mice. Spleen 
cells  from 2-mo-old male trans- 
genie and nontransgenic BXSB, 
CBA/J (I-E  +) and B6.Eot  a trans- 
genic (14) mice was first stained 
with FITC-conjugated anti-mouse 
#  chain mAb (LO-MM-9), and 
then incubated with biotinylated 
anti-I-E (Y-17) mAb, followed by 
PE-conjugated avidin. 
in BXSB mice. This is reminiscent of the prevention of spon- 
taneous autoimmune  diabetes in NOD (I-E-) mice by the 
expression of the I-E antigen through an I-E ot chain trans- 
gene  (10-13).  However,  NOD mice  (H-2g  7) have a unique 
I-A  N~  made of an I-Ac~  a chain and of a distinct  type of 
I-A 13 chain (34).  The mechanisms by which I-E expression 
protects NOD mice are still unclear, and protection is also 
afforded by  the  expression  of I-A  k (35,  36).  It  has  been 
speculated that expression of another class II MHC molecule 
in  the cells  of NOD  mice prevents the peculiar self-anti- 
gen-presenting  property of I-A  N~  In contrast, the I-A ol 
and/3  chains of BXSB  mice  are  apparently conventional 
H-2  b class II MHC molecules.  Expression of I-E molecules 
at the level provided by the H-2  b/a heterozygous  state does 
not protect BXSB mice from their autoimmune  syndrome 
(7),  despite the fact that it is accompanied by a decrease in 
V/35 + and V1311  + T cells comparable with that observed in 
the BXSB-E-1 mice. This suggests that lack of the autoim- 
mune syndrome in the BXSB-E-1 mice may be related to an 
unusually high level of I-E ot chains, as suggested by the very 
high levels of  corresponding mRNA detected (probably rehted 
to the large copy number of E& transgenes carried by these 
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Figure  2.  (A)  Cumulative  mortality 
with glomemlonephritis  in male BXSB 
transgenic (O) and nontransgenic (@) lit- 
termates (15 animals from each group). 
(B-D) Serum levels  of  total IgG, gl,70 IC, 
and  IgG  anti-DNA  autoantibodies  in 
6-too-old BXSB transgenic and nontrans- 
genic male and female mice. 
Figure  3.  (/1) Representative histological appearance of glomerular lesions of kidneys from 8-too-old BXSB nontransgenic  male littermates  showing 
increased glomerular cellularities and obliteration  of the glomeruhr architecture. (B) Representative histological appearance of glomeruli from 8-too-old 
BXSB transgenic males exhibiting  minimal glomerular  changes. Note a marked difference in the size of glomeruli between BXSB transgenic and non- 
transgenic  littermates.  The tissues were  stained with periodic  acid-Schiff reagent  (x 200). 
1193  Merino  et al. mice). Preliminary findings indicate that the second trans- 
genic line, BXSB-E-2, which also carries a high copy number 
of E& transgenes and expresses  Eoe mRNA at a level similar 
to the BXSB-E-1 mice, fails to develop the autoimmune syn- 
drome. An immune deficiency syndrome has been observed 
in mice bearing a high copy number (>50) of the A3  k trans- 
gene (37). It should be emphasized here that the BXSB-E-1 
mice did not show any feature of immune deficiency, had 
an IgG level in male transgenic mice comparable with that 
found in nontransgenic BXSB female mice (Fig. 2 B), and 
displayed a normal immune response against  the T  cell- 
dependent antigen HGG (serum IgG anti-HGG levels 14 d 
after aggregated HGG injection: BXSB-E-1, 528 _+  154 U/ml; 
BXSB, 555  _+  215 U/ml; IgG anti-HGG levels before im- 
munization were <5 U/ml). 
Overexpression ofI-E ot chain in these transgenic mice ap- 
pears to lead to an increased formation of peptides derived 
from this chain which are presented in the groove of I-A  b 
molecules. In mice bearing I-A  b and I-E molecules, it has 
been shown that one of the major self-peptides presented by 
the I-A  b molecules is derived from the I-E ct chain.  It ap- 
pears that the I-Ab-I-Eol peptide complexes are recognized 
by the Y-Ae mAb (22, 23). When this mAb was used to 
stain spleen cells of male mice derived from a cross between 
the BXSB-E-1 and BXSB.H-2  d mice, surface IgM + B cells 
of mice bearing the Eod transgene expressed a higher den- 
sity of the Y-Ae epitope than similar cells from nontrans- 
genic littermates. This was not due to a difference in density 
of the I-A  b molecule on these cells, since B cells from both 
types of mice expressed identical I-A  b density (Fig. 4). The 
likeliest interpretation of this observation is that on splenic 
B cells of mice bearing the transgene, an increased fraction 
of the I-A  ~ molecules  contain in  their groove  the I-E  cr 
chain-derived peptide. 
To explore whether an increased  presentation of I-E cx chain 
peptides by the I-A  b molecule might prevent excessive acti- 
vation of the B cells bearing these peptides, and thus explain 
the lack of autoimmune disease  in the BXSB-E-1 mice, splenic 
I-E+IgM + and I-E-IgM + B cells isolated from 1 yr-old 
BXSB-E-1 male mice were fractionated and compared for their 
spontaneous Ig production. As shown in Fig. 5 A, I-E- B 
cells secreted four to eight times more IgM and IgG than 
I-E + B cells during a 24-h culture, suggesting that I-E- B 
cells were selectively activated in vivo in the BXSB-E-1 mice. 
The smaller spontaneous Ig production of I-E + B cells was 
not due to a general functional deficiency of these cells, since 
after stimulation  with bacterial LPS, they were capable of 
producing IgM Abs at an even higher level than I-E- B cells 
(Fig. 5 B). The relatively lower stimulation of I-E- B cells 
in vitro by LPS is consistent with the notion that these latter 
cells are selectively activated in vivo, as is the case for B cells 
derived from diseased lupus-prone mice (38). 
It may be that a mechanism operates in transgenic mice 
overexpressing I-E oe chains which inhibits the activation of 
B cells by some other indirect way. To explore this possi- 
bility, two types of chimeras were constructed, using non- 
transgenic or transgenic BXSB female mice lethally irradi- 
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Figure  4.  Increased  surface expression  of the Y-Ae epitope on surface 
IgM + B cells expressing the Eod transgene in BXSB mice.  Spleen cells 
from 2-mo-old transgenic and nontransgenic BXSB male mice of H-2  b/a 
haplotype, obtained from a cross between the BXSB-E-1 and BXSB.H-2 a 
(7) mice,  were first stained with FITC-conjugated anti-mouse #  chain 
mAb (LO-MM-9), and then incubated with biotinylated Y-Ae, Y-3P (anti- 
I-Ab), or Y-17 (anti-l-E  d/b) mAb, followed  by PE-conjugated avidin.  As 
controls, spleen cells from BXSB.H-2 a male mice were stained with Y-Ae, 
Y-3P, or Y-17 mAb. 
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Figure  5.  In vitro spontaneous IgM and IgG secretion (.4),  and LPS- 
stimulated IgM production (B) by I-E+IgM + and I-E-IgM + B cells iso- 
lated from the BXSB-E-1 mice. For the spontaneous IgM and IgG secre- 
tion, 10  s I-E+IgM + or I-E-IgM + B cells sorted from spleen cells by a 
FACStar ® were cultured for 24 h at 37°C in a humidified incubator con- 
taining 5% CO2 in air. For the LPS-induced  IgM production, 3  x  104 
I-E+IgM + or I-E-IgM + B cells were stimulated with LPS for 5 d. IgM 
and IgG concentrations in supernatants were determined by ELISA. Rep- 
resentative results of three separate  experiments are shown. 
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Figure  6.  Serum levels of Igh, (@) and I gh  b (O) anti-DNA Abs in four 
different groups of BMC chimeras (4-too after reconstitution).  Results 
are expressed in U/ml, The chimeras are those listed in Table 1. 
nontransgenic BXSB male mice (Table 1). In these chimeras, 
the origin of B cells could be recognized because they bear 
different Igh allotypes. First, irradiated nontransgenic BXSB 
female mice were reconstituted with a mixture of BMC from 
nontransgenic (Igh  ~) and transgenic (Igh  b) male BXSB mice 
(group I). These mice developed lethal glomerulonephritis 
by 8 mo after the reconstitution as did BMC chimeras not 
involving transgenic bone marrow, i.e., female BXSB mice 
reconstituted with nontransgenic male BMC (group III). 
Significantly, Igh allotype analysis of the anti-DNA Abs re- 
vealed that they all originated from the nontransgenic male 
bone marrow population (Fig. 6). Second, irradiated BXSB 
transgenic female mice were reconstituted with a mixture 
of Igh  '  and Igb  b BMC of nontransgenic males (group II). 
These chimeras had a glomerular disease of the same severity, 
and comparable levels of anti-DNA Abs bearing in this con- 
dition the two Ig allotypes. It should be noted that chimeras 
reconstituted with a mixture of BMC from transgenic and 
nontransgenic female mice (group IV) failed to develop a com- 
parable  autoimmune syndrome. 
All this shows that two explanations for the prevention 
of the autoimmune syndrome in the transgenic mice can be 
ruled out: I-E expression by cells of the transgenic animal 
or resulting from the graft of transgenic BMC did not lead 
to the generation of CD8 + regulatory T cells "vetoing" the 
activation of autoreactive cells or to any form of clonal dele- 
tion of potential autoreactive T  cells. It should be empha- 
| 
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Figure 7.  Surface  expression  of  the  Y-Ae epitope  on I-E+IgM  + B ceils  from BMC  chimeric  mice.  2 mo after  the reconstitution,  spleen  ceils  from 
three  groups of  BMC  chimeras were first  stained  with FITC-laI~led Y-17 (anti-I-E)  mAb, then with PE-conjugated goat anti-mouse/~ chain  Abs, 
and finally with biotinylated Y-Ae mAb, followed by Streptavidin-ILED670 TM. (Tbp) Surface I-E and IgM stainings in spleen cells. (Bottom) Expression 
of the Y-Ae epitope in the bE+IgM + and I-E-IgM + B cells.  Note the selective expression of the Y-Ae epitope in the I-E+IgM + B cell population 
in mice of group  I. 
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I-A  b molecule, as  determined by the Y-Ae  staining,  was 
limited only to  I-E + B  cells  derived from the transgenic 
bone marrow population in transgenic and nontransgenic 
double BMC chimeras (group I; Fig. 7),  and that these B 
cells produced far less anti-DNA autoantibodies than I-E- 
B cells in these chimeras (group I; Fig. 6). These results are 
entirely consistent with the hypothesis that a lower activa- 
tion of B cells bearing an I-E oe chain peptide in their I-A  b 
molecule is the mechanism preventing autoimmunity in the 
transgenic mice. 
Our results suggest a novel mechanism explaining how 
the expression of a transgene encoding the I-E ce chain pre- 
vents autoimmune diseases. Since I-E cr chain-derived pep- 
tides apparently have a high affinity for I-A molecules other 
than the I-A  b (39),  this mechanism might also be respon- 
sible for the protection against the development of autoim- 
mune diabetes  by the expression  of an Ecff transgene in 
NOD mice (10-13). Further understanding of the protective 
mechanism(s) conferred by the Ecff transgene may elucidate 
the molecular and cellular bases central to the development 
of murine SLE and possibly of autoimmune diabetes.  These 
mechanisms could have clinical implications in the design of 
future therapeutic strategies with self-peptides  in several au- 
toimmune disorders. 
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